EXPERIMENTAL Article

Isoelectric point region pI≈7.4 as a treasure island of abnormal proteoforms in blood

Mohammad Pirmoradian¹,², Dag Aarsland³, Roman A. Zubarev¹,*

¹Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden; ²Biomotif AB, Stockholm, Sweden; ³Alzheimer's Disease Research Centre, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden;

*Corresponding author: Roman A. Zubarev, PhD, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Scheeles väg 2, SE-17177 Stockholm, Sweden; E-mail: roman.zubarev@ki.se; Phone: +46 8 524 87594

Submitted: July 19th, 2016; Revised: Nov. 16th, 2016; Accepted: Nov. 18th, 2016; Published: Dec. 1st, 2016; Citation: Pirmoradian M, Aarsland D, Zubarev RA. Isoelectric point region pI≈7.4 as a treasure island of abnormal proteoforms in blood. Discoveries 2016, 4(4): e67. DOI: 10.15190/d.2016.14

ABSTRACT

Theoretical distribution of isoelectric points (pI values) of human blood proteins exhibits multimodality with a deep minimum in the range between pI 7.30 and 7.50. Considering that the pH of human blood is 7.4±0.1, normal forms of human proteins tend to eschew this specific pI region, thus avoiding charge neutrality that can result in enhanced precipitation. However, abnormal protein isoforms (proteoforms), which are the hallmarks and potential biomarkers of certain diseases, are likely to be found everywhere in the pI distribution, including this “forbidden” region. Therefore, we hypothesized that damaging proteoforms characteristic for neurodegenerative diseases are best detected around pI≈7.4. Blood serum samples from 14 Alzheimer’s disease patients were isolated by capillary isoelectric focusing and analyzed by liquid chromatography hyphenated with tandem mass spectrometry. Consistent with the pI≈7.4 hypothesis, the 8 patients with fast memory decline had a significantly (p<0.003) higher concentration of proteoforms in the pI=7.4±0.1 region than the 6 patients with a slow memory decline. Moreover, protein compositions differed more from each other than for any other investigated pI region, providing absolute separation of the fast and slow decliner samples. The discovery of the “treasure island” of abnormal proteoforms in form of the pI≈7.4 region promises to boost biomarker development for a range of diseases.

Keywords:
Isoelectric point, proteoforms, Alzheimer’s disease, biomarkers.

Abbreviations:
Alzheimer’s disease (AD); cerebrospinal fluid (CSF); dopamine beta-hydroxylase (DBH); dithiothreitol (DTT); ectonucleotide pyrophosphatase (ENP2); formic acid (FA); false discovery rate (FDR); isoelectric focusing (IEF); insulin-like growth factor 2 (IGF2); insulin-like growth factor 2 binding protein (IGFBP2); liquid chromatography (LC); label-free quantification (LFQ); multijunction capillary isoelectric focusing (MJ-CIEF); mini–mental state examination (MMSE); mass spectrometry (MS); tandem mass spectrometry (MS/MS); molecular weight (MW); orthogonal projections to latent structures for discriminant analysis (OPLS-DA); Parkinson’s disease (PD); isoelectric point (pI); posttranslational modification (PTM); tumor necrosis factor (TNF); transthyretin (TTR); VDP - vitamin D-binding protein (VDP).

INTRODUCTION

Abnormal forms of human proteins (abnormal proteoforms)¹ are often associated with human
disease, such as Alzheimer’s disease (AD), Amyotrophic lateral sclerosis, prion disease, Creutzfeld–Jakob disease, Parkinson’s disease (PD), amyloidosis, and a wide range of other disorders. Abnormal proteoforms arise due to misfolding (as in the above proteopathies), mutations and abnormal splicing, excessive or unusual posttranslational modifications (PTMs), truncation, cross-linking and aggregation, etc. Abnormal proteoforms are used as disease biomarkers and can serve as targets in therapies of the respective diseases.

Abnormalities in the protein primary or higher-order structure as well as in the PTM status result in changes in protein’s physico-chemical properties, such as molecular weight (MW) and isoelectric point pI. The latter is of particular analytical interest, as even a small change in amino acid sequence or 3D structure can result in a pI shift. Protein pI can be estimated from the amino acid sequence using one of the computational approaches. Several groups have computed proteome-wide pI distributions (calculated without the effects of 3D structure, mutations and PTMs), and discovered a general bimodality. The bimodal nature of proteome pI distribution results from the acidic Asp/Glu side chains and basic Lys/Arg side chains. A common feature of many theoretical proteomes is the minimum (trough) between the acidic and basic peaks, found around pI≈7.4. Some researchers believe that this trough is due to a combination of physico-chemical properties of amino acids, protein MW and length distribution, while others find it to be consistent with the tendency of proteins to avoid pI equal to the media’s pH, as at such conditions the proteins acquire neutral overall charge and become prone to aggregation. As experimentally-determined pH values for subcellular compartments differ significantly (lysosome 4.8; vacuole 5.3; Golgi 6.6; endoplasmic reticulum 7.1; cytoplasm 7.3; mitochondrion 7.5; nucleus 7.7; peroxisome 8.2), it was found that the average predicted pI for a subcellular compartment tends to deviate from the subcellular pH, consistent with mitigating against neutral-charge aggregation.

Blood plasma is a major fluid compartment in human body, with a narrow normal range of pH (7.40±0.05). Thus the average pH of human blood is in the middle of the trough observed for the theoretical pI distribution of blood proteome (Figure 1A). Whether such a coincidence is by chance or by design, the density of normal proteoforms in the pI region 7.4±0.1 is very low (ca. 20 times lower than in the region around pI 5.3±0.1). Among few proteins with theoretical pI values close to 7.4 are TNF-receptor isofom TNFRSF1B and alpha-1 antiproteinase isofom SERPINA4. It should be noted, however, that the theoretical calculations can easily give an error of 0.2 pI units or larger.

Abnormal proteoforms usually exhibit a shift in pI due to their deviating 3D structure, mutations, PTMs, truncation as well as aggregation. Random shifting of the protein length while preserving the average amino acid composition characteristic for the proteome leads to fusion of the acidic and basic peaks of the pI distribution into one hump, with the trough at pI≈7.4 eliminated. Increasing the protein length by, e.g., aggregation or complex formation with other proteins, also eliminates the trough. Assuming that every gene product can appear in normal and a multitude of abnormal proteoforms, with the abnormalities’ pIs being distributed according to a bell-shape curve around the pI of the normal form with a standard deviation σ, obtain model distributions of all proteoforms (Figure 1B) for which the ratio R_{abn} between the abnormal and normal proteoforms increases several-folds in the region pI=7.4 compared to other regions (Figure 1C, inset). Note that R_{abn} increases also for extreme pI values, but it is uncertain how extreme pI values of proteoforms can become in practice. The above observations led us to formulate the “pI-pH hypothesis” suggesting that the pI region near the pH of the local media is enriched with abnormal proteoforms. As blood is considered to be optimal bodily fluid for finding biomarkers due to its availability and low invasiveness of sampling, the pI-pH hypothesis, if correct, would open ways for more targeted biomarker discovery.

Testing the pI-pH hypothesis requires isolation of the proteins in a narrow pI range, which can be conveniently performed using isoelectric focusing (IEF). IEF in gel or capillary electrophoresis is often used as one of the dimensions of molecular separation (e.g., in 2D gel electrophoresis). IEF is also a broadly used fractionation technique in blood proteomics studies. However, gel-based methods are tedious and not very well suited for subsequent detection and quantification of proteins with mass spectrometry (MS), due to inevitable losses.
associated with polypeptide extraction from the gel. Capillary-based methods either share the same drawbacks with gel-based methods or suffer from low sample capacity (<1 µg). Recently we have introduced a multijunction capillary isoelectric focusing (MJ-CIEF) device that combines high sample capacity (up to 100 µg), ease and speed of operation (<1 h) with low sample losses (<10%)\textsuperscript{17,18}. This device helped to increase the depth of the proteome analysis of tryptic peptide mixtures\textsuperscript{17} and blood plasma proteins\textsuperscript{18}. Here we employed the MJ-CIEF fractionator for testing the

**Figure 1.** A. Theoretical pI distribution of 10,546 proteins in Plasma Proteome Database. B. The same as in A, assuming that every protein appears in a number of proteoforms with pIs distributed normally around the main proteoform with a standard deviation $\sigma$. C. The ratio between the plots in B and the plot at $\sigma$=0. Inset: increase in the number of proteoforms in the region of pI=7.4±0.05 compared to other pI regions as a function of $\sigma$. 

www.discoveriesjournals.org/discoveries
pI-pH hypothesis in serum of patients with neurodegenerative disorders.

In short, the workflow for hypothesis testing looks as follows (Figure 2). About 3 μL of serum spiked with a mixture of pI markers (synthetic peptides) are first injected into an online desalinator for removing salts interfering with pI separation. After 10 min of dialysis, the sample is transferred into the MJ-CIEF fractionator. The pI separation and focusing step lasts 30-60 min; upon its completion, 10-20 fractions are eluted and collected for further digestion, clean-up and LC-MS/MS analysis. In the acquired LC-MS/MS dataset, the marker peptides are identified and quantified, and thus the fraction representing the pI≈7.4 region is determined. Statistical analysis of the protein abundances will either support or contradict the hypothesis predictions, which are the following. First, the total protein abundance should be higher in the pI≈7.4 region in more severe disease than in healthier samples. Second, the relative protein abundances (normalized by the total protein content in each sample) should differ more between the disease states in that pI region than in other regions.

The above two predictions were tested on serum samples of patients diagnosed with Alzheimer’s disease (AD), the most common disorder causing senile dementia. The onset of this neurodegenerative disease is accompanied by progressive decline in cognitive and functional abilities. Considerable work has been devoted to finding AD biomarkers predicting the rate of disease progression. The commonly used AD molecular biomarkers include increased tau protein and amyloid beta peptide (Aβ42) levels and tau hyperphosphorylation in cerebrospinal fluid (CSF), as well as amyloid beta lesions in brain, the latter detected by positron emission tomography. A drawback of such examinations is the invasive lumbar puncture procedure to acquire CSF and the costly molecular imaging techniques that might not be available to all patients. Therefore, less invasive, more available and preferably more accurate molecular biomarkers are desired. While testing

![Figure 2. Samples: Mental decline in slow decliners (<2 MMSE units per year) and fast decliners (>5 MMSE units per year). General workflow: Each serum sample is spiked with a mixture of pI markers and is injected into the loop. Sample is washed in desalinator for 10 minutes and transferred to pI separation column. Proteins are fractionated by pI and 20 fractions are collected into a 96 well plate. Each fraction is digested and cleaned up prior to LC-MS/MS analysis. Upon peptide identification and quantification, the pI markers peptides are found and the fraction corresponding to pI≈7.4 is identified. The protein abundances in that fraction are statistically analyzed. The experimental pI value of each protein is determined from the abundances of that protein in each fraction.](image-url)
The concept of a proteoform has recently gained much attention. Among the human proteoforms, the abnormal ones are of particular research interest because of their link to disease and diagnostics. Here we provide a general method of enriching the abnormal proteoforms compared to normal forms of the same protein as well as other proteins.

The method works for human blood as well as tissues, and it is based on the common tendency of normal protein forms to avoid the isoelectric point region around pI=7.4 (pH of blood and many other bodily liquids). Thus, isolation of this pI region automatically enriches abnormal proteoforms.

the pI-pH hypothesis, we will examine the possibility of using the pI≈7.4 region for discovering such biomarkers in form of abnormal proteoforms of common blood proteins. One of the reasons for proteoforms to appear in that forbidden region is aggregation, a process characteristic for AD as well as other neurodegenerative disorders. The novel MJ-CIEF device is applied in the current study together with the optimized proteomics techniques developed previously in our lab. For testing the pI-pH hypothesis, patients from Western Norway diagnosed with probable AD and matched for gender (female) and age (77±6 years) were selected. For each patient, the rate of mental decline was determined based on the Mini-mental state examination (MMSE) scores in the initial and follow-up examinations. According to the rate of MMSE score decline, the patients are usually classified as either slow (<2 MMSE units/year) or fast (≥2 MMSE units/year) decliners. Here, the decline rates of slow decliners were <2 MMSE units/year rate, while those of fast decliners - ≥5 MMSE units/year.

MATERIALS AND METHODS

Blood Samples. 14 females from Western Norway diagnosed with probable AD were recruited (Table 1). Selection and diagnostic procedures were performed as previously described. For each patient in the studied cohort, the MMSE score at the moment of blood sample collection was less than 26, and its regression was recorded at follow-up examinations 3 to 5 years after the first diagnosis. The difference between the MMSE scores was divided by the number of years between the examinations, to produce the average annual rate of MMSE decline. Six patients had the annual decline rate less than 2 MMSE units per year (slow decliners), while 8 patients had more than 5 MMSE units per year (fast decliners).

pI markers. Three peptides were synthesized (Peptide 2.0 Inc, USA) to cover the pH range around 7.4, and four more peptides – as controls with pIs in other regions (Table 2). Theoretical isoelectric point of each peptide was calculated by the ExPASy online tool “Compute pI/MW”. None of the peptides had a homologous sequence in human database, which is reflected in their low BLAST scores. The hydrophobicity of peptides was calculated by the online tool “SSRCalc” to ensure elution from the LC column during the LC-MS/MS analysis. Peptides were resuspended in 0.1% formic acid (FA) to a final concentration of 20 mM. A mixture of all seven peptides was prepared and diluted to a final concentration of 1 µg/µL. 0.5 µL of the mixture was added to each sample containing 5 µL of serum.

Desalination and pI separation of blood proteins. 3 µL of each sample were loaded into the MJ-CIEF device. Desalting was performed by buffer exchange in the online desalinator using a washing solution composed of 0.5% Pharmalyte 6.6-7.6, 5% glycerol and 5mM dithiothreitol (DTT) in Milli-Q water at the flow rate of 500 µL/min for 10 min. Thereafter, the sample was transferred for pI separation into the capillary isoelectric focusing column. All external electrolytic buffer solutions (ammonium acetate and ammonium formate) were prepared at 10 mM concentration in degassed Milli-Q water. The buffers set the pH value in each vial, thus creating a nonlinear pH gradient across the whole device: from pH=6.5 in the anodic vial, followed by pH=6.7, 6.9, 7.1, 7.3, 7.5, 7.7 in the interval vials, and to pH=7.9 in the cathodic vial. Floating high voltage of up to -3 kV was applied in the regime of constant current of 40 µA. Isoelectric
focusing was stopped when the voltage increase over time subsided, which usually took less than 50 min. Focused fractions were then mobilized and collected at the flow rate of 0.5 µL/min. A three-time stepwise releasing and refocusing was applied as described in detail previously\textsuperscript{18}. For each sample, 20 fractions were collected.

**Protein digestion.** Proteins in each fraction were digested in solution as described before\textsuperscript{29}. In brief, proteins were reduced with 10 mM DTT and alkylated with iodoacetamide at a final concentration of 10 mM. Proteins were digested with sequencing grade trypsin (Promega, USA) and incubated at 37 °C overnight. The digestion was terminated by the addition of 5% acetic acid (v/v), and the solution was rigorously vortexed for 5 min. All peptide mixtures were purified using acetonitrile elution from Hypersep™ Filter Plate C-18, (Thermo Scientific) and dried out in a SpeedVac to remove the solvent. The dry samples were resuspended in water with 0.1% formic acid and 2% acetonitrile.

**RPLC-MS/MS Analysis.** All fractions were analyzed in a random order. An EASY-Spray LC column (PepMap® RSLC, C18 material with 100 Å pores, 3 µm-bead-packed 15-cm column) from Thermo Scientific was used. The LC gradient lasted 54 min (total LC time – 70 min), while the flow rate was 250 nL/min. The gradient of buffer B (99.9% acetonitrile, 0.1% formic acid) was set as follows: 2% at the start, 5% at 6 min, 19% at 50 min and 30% at 59 min. The gradient was followed by a 5 min washing step at 95% buffer B. Mass spectra were acquired on an Orbitrap Q Exactive Plus mass spectrometer (Thermo Fisher Scientific) in a data-dependent manner using a top-10 MS/MS method. MS spectra were acquired at a resolution of 70,000 with a target value of 3E+06 ions or a maximum accumulation time of 250 ms in an m/z range from 300 to 2000. MS/MS spectra were acquired using HCD fragmentation with a normalized collision energy of 25 at a resolution of 17,500, with a target value of 2E+05 ions or a maximum accumulation time of 120 ms.

**Data analysis.** All 280 raw data files were processed by MaxQuant v. 1.5.0.25, which performed peptide and protein identification and quantification\textsuperscript{30}. As a sequence database, the International Protein Index (human version 3.87; 91,464 protein sequences) was used. Mass tolerance for precursor ions in MS/MS search was 20 ppm in the initial search and 6 ppm in the main search. Cysteine carbamidomethylation was selected as a fixed modification, while acetylation of the protein N-terminus, oxidation of methionine and deamidation of asparagine and glutamine were selected as variable modifications. Up to two missed cleavages were allowed in the matched peptides. The results were filtered to a 1% false discovery rate at both protein and peptide levels\textsuperscript{31}. Further analysis was performed of the data in the output file proteinGroups.txt. The MaxQuant-reported ‘LFQ-intensity’ of each protein was taken as relative protein abundance. Statistical tests and calculations were done using Microsoft Excel and R. The focusing position for each protein on the pI scale was determined as the weighted average of the iBAQ-intensity values in

### Table 1. Information on the patient samples used in the study

| Cohort          | Type    | n   | Gender | Age, year | MMSE baseline | MMSE decline, year⁻¹ |
|-----------------|---------|-----|--------|-----------|---------------|----------------------|
| Slow decliner   | ProbAD  | 6   | female | 78±9      | 22±2          | (1.75±0.2)           |
| Fast decliner   | ProbAD  | 8   | female | 76±5      | 27±2          | (6.3±1.3)            |

### Table 2. Synthetic peptides used as pI markers

| Sequence | pI calc. | Rel. hydrophobicity calc. | BLAST max score |
|----------|----------|---------------------------|-----------------|
| PYFSQAEEK | 6.42     | 21.88                     | 23.1            |
| ELQLSHMIGK | 6.85     | 24.10                     | 22.3            |
| HVIVHELHFK | 7.10     | 29.58                     | 22.7            |
| PFVGHVDHFHK | 7.42     | 22.54                     | 22.7            |
| PHEWHIAHWHR | 7.49     | 27.13                     | 23.5            |
| RPEQSWTCR | 8.07     | 15.12                     | 29.5            |
| KPQFVSIGK | 10.00    | 21.16                     | 22.3            |

www.discoveriesjournals.org/discoveries
individual fractions, as previously described\textsuperscript{17}. The in-silico analysis of theoretical pI values in blood proteome was performed based on the Plasma Proteome Database\textsuperscript{32}. The amino acid sequences of all 10,546 proteins were retrieved from the Ensembl database\textsuperscript{33}. The proteins’ theoretical isoelectric points were calculated using the “seqinR” package in R\textsuperscript{34}. The results were plotted using R in form of a pI histogram.

**RESULTS AND DISCUSSIONS**

*Label free quantification of blood proteins.* Analysis of all LC-MS/MS datasets resulted in quantification of 650 protein groups that passed 1% false discovery rate (FDR) threshold at both peptide and protein levels. To assess the utility of the fractionated proteome for biomarker discovery, the normalized protein abundances were compared between the two groups of patients. Top ten proteins with significant abundance changes (p<0.05) were selected for detailed consideration. Several of these proteins are known to be involved in neurodegenerative disease pathways, e.g., clusterin\textsuperscript{35,36}, beta-Ala-His dipeptidase\textsuperscript{37,38}, dopamine beta-hydroxylase (DBH), insulin-like growth factor and insulin-like growth factor-binding protein\textsuperscript{39,40}, vitamin D-binding protein (VDP), as well as members of the complement system\textsuperscript{41} and serpin family\textsuperscript{40,42} (Figure 3).

There is extensive knowledge implicating the above proteins in AD-related processes. Dopamine beta-hydroxylase (its level is found elevated in fast decliners) is an enzyme that synthesizes norepinephrine from dopamine. Decrease in the activity of this enzyme has been found in cerebrospinal cortex of the AD patients\textsuperscript{43}. Several genetic studies have reported that polymorphism in this gene as well as the proximal region of it promoters are associated with the disease\textsuperscript{44}. Vitamin D-binding protein is a multifunctional molecule whose level is elevated in CSF of AD patients\textsuperscript{45}. Here, VDP level is significantly reduced in fast decliners compared to slow decliners (Figure 3). The role of VDP in binding to and active removing of actin filaments in AD has been suggested\textsuperscript{46}. Other studies reported the role of VDP in suppression of Aβ-mediated pathologies\textsuperscript{47}.

Transgenic mice that over-express the APP Swedish mutation exhibit elevated levels of insulin-like growth factor 2 (IGF2), insulin-like growth factor 2 binding protein (IGFBP2), and ectonucleotide pyrophosphatase (ENP2) well before the onset of Aβ deposition\textsuperscript{48,49}. Both IGF2 and the IGFBP2 have been reported as markers in patients with neurodegenerative diseases\textsuperscript{39}. A possible stimulatory effect of soluble Aβ peptide in activation of these proteins in AD brain have been suggested in an in vivo study\textsuperscript{39}. The level of IGF2 is found to be significantly reduced in fast decliners compared to slow decliners (Figure 3).

Clusterin has been found in amyloid plaques\textsuperscript{35}. Clusterin can also play a chaperone role in degradation of the Aβ peptide\textsuperscript{35}. Clusterin has been suggested as a biomarker candidate for multiple sclerosis, with lower levels of protein in patients compared to healthy controls\textsuperscript{50}. However, in AD and PD the clusterin abundance has been found elevated\textsuperscript{51}. Here, the clusterin abundance is found to be significantly higher in fast decliners than in slow decliners.

Beta-Ala-His dipeptidase (found here at elevated levels in fast decliners) has been implicated in regulation of the immune response\textsuperscript{37}.

*Narrow pI≈7.4 region.* The fraction with 7.1 < pH < 7.5 was identified by means of spiked pI markers.
Isoelectric point of abnormal proteoforms in blood

The total abundance of the proteins in this fraction was compared between the two groups of patients. As a reference value, the same comparison was also performed for the neighboring fractions. A significantly changed (elevated) total protein concentration was only found in the pI≈7.4 fraction, in agreement with our hypothesis (Figure 4). The median total protein abundance in this region was more than 4 times higher in fast decliners than in slow decliners. The protein concentration of this narrow pH region could therefore be used for predicting the speed of mental decline in AD patients.

An OPLS-DA model built based on protein abundances in the pI≈7.4 region resulted in perfect separation of the patient groups, as shown in Figure 5A. Most proteins contributing to the separation are either members of immunoglobulin family, or have...
known roles in AD\textsuperscript{52,53}, including carbonic anhydrase II, glucokinase, transthyretin, insulin-like growth factor binding protein 3, ganglioside GM2 activator, apolipoprotein C-I, calmodulin-like protein 5, and caspase-14.

Carbonic anhydrase II has a role in regulating the pH and also synaptic transportation. Several studies reported the elevated levels of this protein in both Down syndrome and AD\textsuperscript{5}. Glucokinase triggers the shifts in metabolism or cell function in response to glucose level. The correlation between the expression of this gene and the mechanisms of insulin action and insulin resistance has been reported in neurodegenerative diseases, including AD\textsuperscript{54}. The role of transthyretin (TTR) in AD is reported to be the same as for vitamin D binding protein, which is detoxification of neuronal cells from actin fibrils and amyloid beta\textsuperscript{48}. In transgenic mouse models, the TTR level increased before appearance of amyloid plaques, suggesting TTR to be an early biomarker of AD\textsuperscript{48,49}. As for ganglioside GM2 activator, the level and density of GM2 increase in neurodegenerative diseases\textsuperscript{54}. Calmodulin is one of the primary calcium signal transducer, which regulates the calcium balance in the cell. Many studies suggested the disruption of calcium signaling as the cause of neuronal apoptosis in AD, and reported the role of Calmodulin as well as Calmodulin binding domain in AD\textsuperscript{55}.

In the generated OPLS-DA model, R\textsuperscript{2} (fitness) was 97%, and Q\textsuperscript{2} (predictive power) was 72%. The high predictive power demonstrates the analytical potential of the pI≈7.4 isolation approach.

For proteins discussed above, the theoretical pI based on the amino acid sequence is listed in Table 3. Most proteins here perform carrier function, such as transthyretin, apolipoprotein C-I and insulin-like growth factor binding protein 3 and calmodulin-like protein 5. Thus the pI-shift to ≈7.4 could be due to the coupled form of the protein with a carried compound. For proteins such as caspase and complement factors, concatenation can also be the cause of the pI shift.

We were unable to detect any PTMs on the identified peptides that could account for the observed pI shift of the proteins. Therefore, further analyses, e.g., at the level of intact proteins and protein complexes, are needed to resolve this issue.

**CONCLUSION**

Here we tested the pI-pH hypothesis by fractionating blood serum proteins using capillary isoelectric focusing. pI-based fractionation prior to shotgun proteomics increased the depth of proteome analysis, as expected. Consistent with the pI-pH hypothesis, the protein concentration in the pI=7.4±0.1 region turned out to be significantly higher (p<0.003) in patients with fast memory decline than in slow decliners. The proteins identified and quantified in this pI region provided an OPLS-DA model with excellent predictive power. This protein panel encompasses several previously reported AD biomarkers as well as a few

| Protein                                | Theoretical pI | Median pI in slow decliners | Median pI in fast decliners |
|----------------------------------------|----------------|----------------------------|-----------------------------|
| Carbonic anhydrase 2                   | 6.87           | Not observed               | 7.4                         |
| Apolipoprotein C-I                     | 8.01           | < 6.4                      | 7.4                         |
| Transthyretin                          | 5.49           | 7.1                        | 7.4                         |
| Caspase-14                             | 6.09           | < 6.4                      | 7.4                         |
| Serpin B3                              | 6.35           | < 6.4                      | 7.4                         |
| Glucokinase                            | 5.1            | 7.1                        | 7.4                         |
| IGFBP-3                                | 9.03           | 7.1                        | 7.4                         |
| Ganglioside GM2 activator              | 5.17           | 7.1                        | 7.4                         |
| Calmodulin-like protein 5              | 5.34           | 7.1                        | 7.4                         |
novel biomarker candidates. At this moment it is unclear why these proteins appear around pI=7.4, since their theoretical pIs are well outside this region. Aggregation, truncation and posttranslational modifications are the prime candidates. Further investigation is needed for studying the correlation between the protein concentration at pI=7.4 and the disease state, as well as the specificity of this marker for different neurodegenerative diseases. But it is now certain that the pI=7.4 region represents a true “treasure island” of abnormal proteoforms.

Acknowledgments
This work was supported by the Swedish Research Council (grant 2011-3699), VINNOVA Foundation (grants within the EuroStar 2010 and 2015 Programs), and the Knut and Alice Wallenberg Foundation (grant KAW 2010.0022 to RZ). This study was conducted according to the guidelines laid down in the Declaration of Helsinki. All procedures involving human subjects were approved by the Ethics Review Board of the University of Bergen (Approval number 2013/914-31/4). Written informed consent was obtained from all subjects.

Conflict of Interest:
The authors declare no conflicts of interest.

References:
1. Smith, L. M., Kelleher, N. L. & Consortium for Top Down, P. Proteoform: a single term describing protein complexity. Nat Methods, 2013; 10: 186-187.
2. Tazi, J., Bakkour, N. & Stamm, S. Alternative splicing and disease. Biochim Biophys Acta, 2009; 1792: 14-26.
3. Weiller, G. F., Caraux, G. & Sylvester, N. The modal distribution of protein isoelectric points reflects amino acid properties rather than sequence evolution. Proteomics, 2004; 4: 943-949.
4. Theberge, R., Infusini, G., Tong, W., McComb, M. E. & Costello, C. E. Top-Down Analysis of Small Plasma Proteins Using an LTQ-Orbitrap. Potential for Mass Spectrometry-Based Clinical Assays for Transthyretin and Hemoglobin. Int J Mass Spectrom, 2011; 300: 130-142.
5. Righetti, P. G., Sebastiano, R. & Citterio, A. Capillary electrophoresis and isoelectric focusing in peptide and protein analysis. Proteomics, 2013; 13: 325-340.
6. Halligan, B. D. et al. ProMoST (Protein Modification Screening Tool): a web-based tool for mapping protein modifications on two-dimensional gels. Nucleic Acids Res, 2004; 32: W638-644.
7. Sillero, A. & Maldonado, A. Isoelectric point determination of proteins and other macromolecules: oscillating method. Comput Biol Med, 2006; 36: 157-166.
8. Jang, B. G. et al. Plasma carbonic anhydrase II protein is elevated in Alzheimer's disease. J Alzheimers Dis, 2010; 21: 939-945.
9. Wu, S. et al. Multi-modality of pI distribution in whole proteome. Proteomics, 2006; 6: 449-455.
10. Chan, P., Lovric, J. & Warwicker, J. Subcellular pH and predicted pH-dependent features of proteins. Proteomics, 2006; 6: 3494-3501.
11. Chan, P. & Warwicker, J. Evidence for the adaptation of protein pH-dependence to subcellular pH. BMC Biol, 2009; 7: 69.
12. Waugh A, G. A. Anatomy and Physiology in Health and Illness. 10th edition edn, (Churchill Livingstone Elsevier, 2007).
13. Halligan, B. D. ProMoST: a tool for calculating the pI and molecular mass of phosphorylated and modified proteins on two-dimensional gels. Methods Mol Biol, 2009; 527: 283-298.
14. Chatterjee, R. et al. Isolation and characterization of a new hemoglobin derivative cross-linked between the alpha chains (lysine 99 alpha 1-lysine 99 alpha 2). J Biol Chem, 1986; 261: 9929-9937.
15. Carugo, O. Isoelectric points of multi-domain proteins. Bioinformation, 2007; 2, 101-104.
16. Pernemalm, M. & Lehtio, J. Mass spectrometry-based plasma proteomics: state of the art and future
Isoelectric point of abnormal proteoforms in blood

11

www.discoveriesjournals.org/discoveries

outlook. Expert review of proteomics, 2014; 11: 431-448.
17. Pirmoradian, M., Zhang, B., Chingin, K., Astorga-Wells, J. & Zubarev, R. A. Membrane-assisted isoelectric focusing device as a micropreparative fractionator for two-dimensional shotgun proteomics. Analytical chemistry, 2014; 86: 5728-5732.
18. Pirmoradian, M., Astorga-Wells, J. & Zubarev, R. A. Multijunction capillary isoelectric focusing device combined with online membrane-assisted buffer exchanger enables isoelectric point fractionation of intact human plasma proteins for biomarker discovery. Analytical chemistry, 2015.
19. Hye, A. et al. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement., 2014; 10: 799-807, e792.
20. Humpel, C. Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol, 2011; 29: 26-32.
21. Moya-Alvarado, G., Gershoni-Emek, N., Perlson, E. & Bronfman, F. C. Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain? Molecular & cellular proteomics: MCP, 2016; 15: 409-425.
22. Lista, S., Faltraco, F., Pmrulovic, D. & Hampil, H. Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog Neurobiol, 2013; 101-102: 1-17.
23. Chingin, K., Astorga-Wells, J., Pirmoradian Najafabadi, M., Lavold, T. & Zubarev, R. A. Separation of polypeptides by isoelectric point focusing in electrospray-friendly solution using a multiple-junction capillary fractionator. Analytical chemistry, 2012; 84: 6856-6862.
24. Aarsland, D. et al. Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord, 2008; 26: 445-452.
25. Doody, R. S., Massman, P. & Dunn, J. K. A method for estimating progression rates in Alzheimer disease. Arch Neurol, 2001; 58: 449-454.
26. Walker, J. M. The proteomics protocols handbook. (Humana Press, 2005).
27. Altschul, S. F. A protein alignment scoring system sensitive at all evolutionary distances. J Mol Evol, 1993; 36, 290-300.
28. Krokhin, O. V. & Spicer, V. Predicting peptide retention times for proteomics. Curr Protoc Bioinformatics, 2010; 13: Unit 13 14.
29. Pirmoradian, M. et al. Rapid and deep human proteome analysis by single-dimension shotgun proteomics. Molecular & cellular proteomics: MCP, 2013; 12: 3330-3338.
30. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol, 2008; 26: 1367-1372.
31. Cox, J. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Molecular & cellular proteomics: MCP, 2014; 13: 2513-2526.
32. Nanjappa, V. et al. Plasma Proteome Database as a resource for proteomics research: 2014 update. Nucleic Acids Res, 2014; 42: D959-965.
33. Cunningham, F. et al. Ensembl 2015. Nucleic Acids Res, 2015; 43: D662-669.
34. Charif D., L. J. R. in Biological and Medical Physics, Biomedical Engineering (ed Porto M. Bastolla U., Roman H.E., Vendruscolo M.) 207-232 (Springer Verlag, 2007).
35. Schjeide, B. M. et al. The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry, 2011; 68: 207-213.
36. Thambisetty, M. et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry, 2010; 67: 739-748.
37. Kroksveen, A. C., Opsahl, J. A., Aye, T. T., Ulvik, R. J. & Berven, F. S. Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J Proteomics, 2011; 74: 371-388.
38. Zurbig, P. & Jahn, H. Use of proteomic methods in the analysis of human body fluids in Alzheimer research. Electrophoresis, 2012, 33: 3617-3630.
39. de la Monte, S. M. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res, 2012; 9: 35-66.
40. Doecke, J. D. et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol, 2012; 69: 1318-1325.
41. Bergamaschini, L. et al. Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a Clq-independent manner. Clin Exp Immunol, 1999; 115: 526-533.
42. Liao, P. C., Yu, L., Kuo, C. C., Lin, C. & Kuo, Y. M. Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease. Proteomics Clin Appl, 2007; 1: 506-512.
43. Cross, A. J. et al. Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br Med J (Clin Res Ed), 1981; 282: 93-94.
44. Mustapic, M. et al. The catecholamine biosynthetic enzyme dopamine beta-hydroxylase (DBH): first genome-wide search positions trait-determining variants acting additively in the proximal promoter. Hum Mol Genet, 2014; 23: 6375-6384.
45. Bishnoi, R. J., Palmer, R. F., Royall, D. R. Vitamin D binding protein as a serum biomarker of Alzheimer's disease. J Alzheimers Dis, 2015; 43; 37-45.
46. Gressner, O. A. et al. Questioning the role of actin-free Gc-Globulin as actin scavenger in neurodegenerative central nervous system disease: relationship to S-100B levels and blood-brain barrier function. *Clin Chim Acta*, 2009; 400: 86-90.
47. Moon, M. et al. Vitamin D-binding protein interacts with Abeta and suppresses Abeta-mediated pathology. *Cell Death Differ*, 2013; 20: 630-638.
48. Stein, T. D. & Johnson, J. A. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. *J Neurosci*, 2002; 22: 7380-7388.
49. Lazarov, O. et al. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. *Cell*, 2005; 120: 701-713.
50. Comabella, M. et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. *Brain*, 2010; 133: 1082-1093.
51. Yin, G. N., Lee, H. W., Cho, J. Y. & Suk, K. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. *Brain Res*, 2009; 1265: 158-170.
52. Hashimoto, Y. et al. Secreted calmodulin-like skin protein inhibits neuronal death in cell-based Alzheimer's disease models via the heterotrimeric Humanin receptor. *Cell Death Dis*, 2013; 4: e555
53. Petit-Turcotte, C. et al. Apolipoprotein C-I expression in the brain in Alzheimer's disease. *Neurobiol Dis*, 2001; 8: 953-963.
54. Plum, L., Schubert, M. & Bruning, J. C. The role of insulin receptor signaling in the brain. *Trends Endocrinol Metab*, 2005; 16: 59-65.
55. O'Day, D. H. & Myre, M. A. Calmodulin-binding domains in Alzheimer's disease proteins: extending the calcium hypothesis. *Biochem Biophys Res Commun*, 2004; 320: 1051-1054.

DISCOVERIES is a high quality peer-reviewed, open access, online, multidisciplinary and integrative journal, publishing high impact and innovative manuscripts from all areas related to MEDICINE, BIOLOGY and CHEMISTRY; © 2016, Applied Systems